Studies on the application of recombinant human endostatin (RH-endostatin) intraperitoneal perfusion in gastric cancer (GC) with malignant ascites are limited.

To explore the effectiveness, prognosis, and safety of intraperitoneal RH-endostatin perfusion in treating patients with GC and malignant ascites.

Patients with GC and malignant ascites were divided into the cisplatin intraperitoneal perfusion (control group) group and the cisplatin combined with RH-endostatin intraperitoneal perfusion group (RH-endostatin group). Efficient ascites control, overall survival (OS), quality of life, and adverse events were observed, and possible influencing factors on prognosis outcomes analyzed.

We identified no significant differences in baseline characteristics between the control and RH-endostatin groups. The latter group had higher ascites control rates than the control group. Treatment methods were identified as an independent OS factor. Clinically, RH-endostatin-treated patients had significantly improved OS rates when compared with control patients, particularly in those with small and moderate ascites volumes. Quality of life improvements in control patients were significantly lower when compared with RH-endostatin patients. Adverse events were balanced between the groups.

Overall, intraperitoneal RH-endostatin improved treatment efficacy and prolonged prognosis in patients with GC and malignant ascites. This approach may benefit further clinical applications for treating GC.

• Gastric cancer
• Recombinant human endostatin
• Peritoneal metastasis
• Malignant ascites
• Cisplatin
• Efficacy
• Prognosis

• Mesenchymal stem cells
• Non-viral gene modification
• Peritoneal carcinomatosis

• Animals
• Mesenchymal Stem Cells/metabolism
• Mesenchymal Stem Cells/cytology
• Peritoneal Neoplasms/therapy
• Peritoneal Neoplasms/secondary
• Peritoneal Neoplasms/genetics
• Peritoneal Neoplasms/pathology
• Humans
• Mesenchymal Stem Cell Transplantation
• Pentosyltransferases/genetics
• Pentosyltransferases/metabolism
• Transgenes
• Cell Line, Tumor
• Interferon-beta/metabolism
• Interferon-beta/genetics
• Xenograft Model Antitumor Assays
• Cytosine Deaminase/genetics
• Cytosine Deaminase/metabolism
• Mice
• Female

• colorectal
• curcumin
• hyperthermic
• mitomycin-C
• peritoneal carcinomatosis

This study aims to evaluate the safety and efficacy of lobaplatin in prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer.

Advanced gastric cancer patients who underwent radical gastric resection and/or prophylactic HIPEC were systematically reviewed in our department from January 2016 to June 2017. All enrolled patients were grouped in either HIPEC or non-HIPEC groups. Clinical data were collected and analyzed.

A total of 129 patients were enrolled with 61 cases in the HIPEC group and 68 in the non-HIPEC group. The two groups were well balanced in terms of clinical characteristics. In patients of the HIPEC group, three suffered leakage from the duodenal stump or anastomosis, one suffered abnormal bleeding and two were found to have abnormal routine blood tests; no significant difference in adverse events between groups, however, was noted (p > 0.05) and most patients recovered uneventfully. During follow-up, peritoneal recurrence was significantly less among HIPEC patients (p = 0.029), with only three suffering peritoneal recurrence, as compared to 12 non-HIPEC patients. In addition, the estimated illness-specific 3-year disease-free survival rate was significantly higher in the HIPEC group as compared to the non-HIPEC group (89.4% vs.73.9%; p = 0.031).

Lobaplatin in prophylactic HIPEC is safe for advanced gastric cancer patients after treatment by radical resection and can effectively improve illness-specific 3-year disease-free survival.

• gastric cancer
• hyperthermic intraperitoneal chemotherapy
• lobaplatin
• safety

With the increasing number of cancer treatments, the emergence of multidisciplinary teams (MDTs) provides patients with personalized treatment options. In recent years, artificial intelligence (AI) has developed rapidly in the medical field. There has been a gradual tendency to replace traditional diagnosis and treatment with AI. IBM Watson for Oncology (WFO) has been proven to be useful for decision-making in breast cancer and lung cancer, but to date, research on gastric cancer is limited.

This study compared the concordance of WFO with MDT and investigated the impact on patient prognosis.

This study retrospectively analyzed eligible patients (N=235) with gastric cancer who were evaluated by an MDT, received corresponding recommended treatment, and underwent follow-up. Thereafter, physicians inputted the information of all patients into WFO manually, and the results were compared with the treatment programs recommended by the MDT. If the MDT treatment program was classified as “recommended” or “considered” by WFO, we considered the results concordant. All patients were divided into a concordant group and a nonconcordant group according to whether the WFO and MDT treatment programs were concordant. The prognoses of the two groups were analyzed.

The overall concordance of WFO and the MDT was 54.5% (128/235) in this study. The subgroup analysis found that concordance was less likely in patients with human epidermal growth factor receptor 2 (HER2)-positive tumors than in patients with HER2-negative tumors (P=.02). Age, Eastern Cooperative Oncology Group performance status, differentiation type, and clinical stage were not found to affect concordance. Among all patients, the survival time was significantly better in concordant patients than in nonconcordant patients (P<.001). Multivariate analysis revealed that concordance was an independent prognostic factor of overall survival in patients with gastric cancer (hazard ratio 0.312 [95% CI 0.187-0.521]).

The treatment recommendations made by WFO and the MDT were mostly concordant in gastric cancer patients. If the WFO options are updated to include local treatment programs, the concordance will greatly improve. The HER2 status of patients with gastric cancer had a strong effect on the likelihood of concordance. Generally, survival was better in concordant patients than in nonconcordant patients.

• Watson for Oncology
• artificial intelligence
• concordance
• gastric cancer
• multidisciplinary team

• cytoreductive surgery
• gastric cancer
• hyperthermic intraperitoneal chemotherapy
• peritoneal metastases

• Adult
• Aged
• Antineoplastic Agents/administration & dosage
• Antineoplastic Agents/adverse effects
• Antineoplastic Agents/therapeutic use
• Combined Modality Therapy
• Female
• Humans
• Hyperthermia, Induced/adverse effects
• Hyperthermia, Induced/methods
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Neoplasm Staging
• Retrospective Studies
• Socioeconomic Factors
• Stomach Neoplasms/pathology
• Stomach Neoplasms/surgery
• Stomach Neoplasms/therapy
• Survival Analysis

• Sp1
• X-ray repair cross complementing group 1 (XRCC1)
• chemoresistance
• gastric cancer
• mitomycin C (MMC)

Background: Cytoreductive surgery (CRS), followed by hyperthermic intraperitoneal chemotherapy (HIPEC), combines radical surgery with abdominal heated chemotherapy, constituting a multimodal treatment approach. Since clear standards for HIPEC conduct in colorectal carcinoma (CRC) are lacking, we aimed to provide a comprehensive structured survey. Data sources and study eligibility criteria: A systematic literature search was performed in PubMed, with keywords “HIPEC” and “colorectal cancer”, according to established guidelines. Articles were systematically screened, selecting 87 publications complemented by 48 publications identified through extended search for subsequent synthesis and evaluation, extracting inter alia details on used drugs, dosage, temperature, exposure times, and carrier solutions. Results: Compiled publications contained 171 reports on HIPEC conduct foremost with mitomycin C and oxaliplatin, but also other drugs and drug combinations, comprising at least 60 different procedures. We hence provide an overview of interconnections between HIPEC protocols, used drugs and carrier solutions as well as their volumes. In addition, HIPEC temperatures and dosing benchmarks, as well as an estimate of in vivo resulting drug concentrations are demonstrated. Conclusions and implications: Owing to recent developments, HIPEC conduct and practices need to be reassessed. Unfortunately, imprecise and lacking reporting is frequent, which is why minimal information requirements should be established for HIPEC and the introduction of final drug concentrations for comparability reasons seems sensible.

• PRISMA
• colorectal carcinoma
• cytoreductive surgery
• hyperthermic intraperitoneal chemotherapy
• peritoneal metastasis
• systematic review

To evaluate the clinical efficacy of intraperitoneal hyperthermic perfusion chemotherapy for patients with gastric cancer (GC) peritoneal metastasis and its impact on immune function and prognosis.

A retrospective analysis was performed of 113 patients with GC treated at the First Affiliated Hospital of Zhengzhou University between June 2010 and March 2013. The patients were randomly divided into an observation group (54 cases) and a control group (59 cases). Patients in the control group were treated with conventional intravenous chemotherapy, and patients in the observation group were treated with intraperitoneal hyperthermic perfusion chemotherapy. The clinical efficacy, related indicators of recurrence and metastasis, tumor markers, T-lymphocyte subsets, quality of life, and occurrence of adverse reactions after chemotherapy was compared between the two groups of patients.

The total effective rate and disease control rate in the observation group were significantly higher than those in the control group (P < 0.05). The levels of serum carbohydrate antigen 199 (CA199), CA724, and carcinoembryonic antigen (CEA) were significantly lower in the observation group than in the control group (P < 0.05). After treatment, serum vascular endothelial growth factor (VEGF), osteopontin (OPN), soluble apoptotic factor (sFas), and matrix metalloproteinase-9 (MMP-9) levels were significantly lower in the observation group than in the control group (P < 0.05). CD3⁺ T cells, CD4⁺ T cells, CD4⁺/CD8⁺ ratio, and B cells in the peripheral blood were significantly higher in the observation group than in the control group, while CD8⁺ T cells and NK cells were significantly lower than those of the control group (P < 0.05). The improvement of KPS score after treatment, the recurrence rate at 2 years, the 3-year survival rate, and the 5-year survival rate were significantly better in the observation group than in the control group (P < 0.05). The incidence of adverse reactions after chemotherapy was not statistically different between the two groups (P > 0.05).

Peritoneal hyperthermic perfusion chemotherapy can improve clinical efficacy, tumor markers and related indicators of recurrence and metastasis, as well as the patient's immune function and quality of life of patients with GC peritoneal metastasis, without increasing the incidence of adverse reactions.

• Intraperitoneal hyperthermic perfusion chemotherapy
• Efficacy
• Gastric cancer
• Recurrence and metastasis
• Immune function

• Advanced hepatocellular carcinoma
• Network meta-analysis
• Sorafenib
• TACE
• Transarterial chemoembolization

• Cisplatin
• HIPEC
• Leukopenia
• Melphalan
• Mitomycin-c
• Thrombocytopenia

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols/therapeutic use
• Chemotherapy, Cancer, Regional Perfusion
• Cisplatin/administration & dosage
• Combined Modality Therapy
• Cytoreduction Surgical Procedures
• Female
• Follow-Up Studies
• Humans
• Hyperthermia, Induced
• Incidence
• Male
• Melphalan/administration & dosage
• Middle Aged
• Mitomycin/administration & dosage
• Neutropenia/epidemiology
• Peritoneal Neoplasms/pathology
• Peritoneal Neoplasms/therapy
• Prognosis
• Retrospective Studies
• Saudi Arabia/epidemiology
• Thrombocytopenia/epidemiology
• Young Adult